Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Catholics and others around the world have been praying for the pope, a liberal reformer who has led the Church for almost 12 years.

The Vatican said the pope responded well to the treatment, with a good level of gas exchange, and remained conscious and alert at all times.

David Koma has turned the page at Blumarine. Roses are thornier, red is blood-stained—romance is edgier, nocturnal. His ...

Boston Mayor Michelle Wu joined WBUR’s Morning Edition to discuss her upcoming appearance before the House Oversight ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Tiziana Life Sciences ( ($TLSA) ) has shared an update. On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a ...

Worry over Pope Francis’ health has fueled speculation as to who could replace the pontiff if his condition worsens.